2023 年印度锡金东区宫颈癌筛查中通过家庭自采样进行 HPV 初检与使用醋酸进行目检的成本效用分析比较

Roopa Hariprasad, Bhavani Shankara Bagepally, Sajith Kumar, Sangeeta Pradhan, Deepsikka Gurung, Harki Tamang, Arpana Sharma, Tarun Bhatnagar
{"title":"2023 年印度锡金东区宫颈癌筛查中通过家庭自采样进行 HPV 初检与使用醋酸进行目检的成本效用分析比较","authors":"Roopa Hariprasad, Bhavani Shankara Bagepally, Sajith Kumar, Sangeeta Pradhan, Deepsikka Gurung, Harki Tamang, Arpana Sharma, Tarun Bhatnagar","doi":"10.1101/2024.03.03.24303673","DOIUrl":null,"url":null,"abstract":"Introduction\nPrimary Human Papilloma Virus (HPV) testing offers higher sensitivity and specificity over Visual Inspection using Acetic acid (VIA) in cervical cancer screening. Self-sampling is a promising strategy to boost participation and reduce disparities. However, concerns about the initial costs hinder HPV testing adoption in low and middle-income countries. This study assesses the cost-utility of home-based HPV self-sampling versus VIA for cervical cancer screening in India Methods\nA cross-sectional study was conducted in East district, Sikkim, India, comparing the costs and utility outcomes of population-based cervical cancer screening through VIA and primary HPV screening through self-sampling. Cost-related data were collected from April 2021 to March 2022 using the bottom-up micro-costing method, while utility measures were collected prospectively using the EuroQoL-5D-5L questionnaire. The utility values were converted into quality-adjusted life days (QALDs) for an 8-day period. The willingness to pay threshold (WTP) was based on per capita GDP for 2022. . If the calculated Incremental Cost-Effectiveness Ratio (ICER) value is lower than the WTP threshold, it signifies that the intervention is cost-effective. Results\nThe study included 95 women in each group of cervical cancer screening with VIA & HPV self-sampling. For eight days, the QALD was found to be 7.977 for the VIA group and 8.0 for the HPV group. The unit cost per woman screened by VIA and HPV self-testing was ?1,597 (US$ 19.2) and ?1,271(US$ 15.3), respectively. The ICER was ?-14,459 (US$ -173.6), which was much below the WTP threshold for eight QALDs, i.e. ? 4,193 (US$ 50.4). Conclusion\nThe findings support HPV self-sampling as a cost-effective alternative to VIA. This informs policymakers and healthcare providers for better resource allocation in cervical cancer screening in Sikkim.","PeriodicalId":501072,"journal":{"name":"medRxiv - Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-utility analysis of primary HPV testing through home-based self-sampling in comparison to visual inspection using acetic acid for cervical cancer screening in East district, Sikkim, India, 2023\",\"authors\":\"Roopa Hariprasad, Bhavani Shankara Bagepally, Sajith Kumar, Sangeeta Pradhan, Deepsikka Gurung, Harki Tamang, Arpana Sharma, Tarun Bhatnagar\",\"doi\":\"10.1101/2024.03.03.24303673\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction\\nPrimary Human Papilloma Virus (HPV) testing offers higher sensitivity and specificity over Visual Inspection using Acetic acid (VIA) in cervical cancer screening. Self-sampling is a promising strategy to boost participation and reduce disparities. However, concerns about the initial costs hinder HPV testing adoption in low and middle-income countries. This study assesses the cost-utility of home-based HPV self-sampling versus VIA for cervical cancer screening in India Methods\\nA cross-sectional study was conducted in East district, Sikkim, India, comparing the costs and utility outcomes of population-based cervical cancer screening through VIA and primary HPV screening through self-sampling. Cost-related data were collected from April 2021 to March 2022 using the bottom-up micro-costing method, while utility measures were collected prospectively using the EuroQoL-5D-5L questionnaire. The utility values were converted into quality-adjusted life days (QALDs) for an 8-day period. The willingness to pay threshold (WTP) was based on per capita GDP for 2022. . If the calculated Incremental Cost-Effectiveness Ratio (ICER) value is lower than the WTP threshold, it signifies that the intervention is cost-effective. Results\\nThe study included 95 women in each group of cervical cancer screening with VIA & HPV self-sampling. For eight days, the QALD was found to be 7.977 for the VIA group and 8.0 for the HPV group. The unit cost per woman screened by VIA and HPV self-testing was ?1,597 (US$ 19.2) and ?1,271(US$ 15.3), respectively. The ICER was ?-14,459 (US$ -173.6), which was much below the WTP threshold for eight QALDs, i.e. ? 4,193 (US$ 50.4). Conclusion\\nThe findings support HPV self-sampling as a cost-effective alternative to VIA. This informs policymakers and healthcare providers for better resource allocation in cervical cancer screening in Sikkim.\",\"PeriodicalId\":501072,\"journal\":{\"name\":\"medRxiv - Health Economics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Health Economics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.03.03.24303673\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Health Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.03.03.24303673","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:在宫颈癌筛查中,初级人类乳头瘤病毒(HPV)检测比醋酸目视检查(VIA)具有更高的灵敏度和特异性。自我采样是提高参与率和减少差异的一项有前途的策略。然而,对初始成本的担忧阻碍了中低收入国家采用 HPV 检测。本研究评估了印度宫颈癌筛查中家庭HPV自采样与VIA的成本效用方法在印度锡金东区进行了一项横断面研究,比较了通过VIA进行人群宫颈癌筛查和通过自采样进行初级HPV筛查的成本和效用结果。成本相关数据是在 2021 年 4 月至 2022 年 3 月期间采用自下而上的微观成本计算方法收集的,而效用指标则是采用 EuroQoL-5D-5L 问卷进行前瞻性收集的。效用值被转换为 8 天的质量调整生命天数(QALDs)。支付意愿阈值(WTP)基于 2022 年的人均 GDP。.如果计算出的增量成本效益比 (ICER) 值低于 WTP 临界值,则表明干预措施具有成本效益。结果该研究在每组 95 名妇女中进行了宫颈癌筛查(VIA & HPV 自我采样)。结果发现,VIA 组 8 天的 QALD 为 7.977,HPV 组为 8.0。每名接受 VIA 和 HPV 自我检测的妇女的单位成本分别为 1,597 美元(19.2)和 1,271 美元(15.3)。ICER为-14,459(-173.6美元),远低于8个QALD的WTP阈值,即4,193(50美元)。4,193(50.4 美元)。结论研究结果表明,HPV 自我采样是一种替代 VIA 的具有成本效益的方法。这为锡金的政策制定者和医疗服务提供者提供了信息,以更好地分配宫颈癌筛查的资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cost-utility analysis of primary HPV testing through home-based self-sampling in comparison to visual inspection using acetic acid for cervical cancer screening in East district, Sikkim, India, 2023
Introduction Primary Human Papilloma Virus (HPV) testing offers higher sensitivity and specificity over Visual Inspection using Acetic acid (VIA) in cervical cancer screening. Self-sampling is a promising strategy to boost participation and reduce disparities. However, concerns about the initial costs hinder HPV testing adoption in low and middle-income countries. This study assesses the cost-utility of home-based HPV self-sampling versus VIA for cervical cancer screening in India Methods A cross-sectional study was conducted in East district, Sikkim, India, comparing the costs and utility outcomes of population-based cervical cancer screening through VIA and primary HPV screening through self-sampling. Cost-related data were collected from April 2021 to March 2022 using the bottom-up micro-costing method, while utility measures were collected prospectively using the EuroQoL-5D-5L questionnaire. The utility values were converted into quality-adjusted life days (QALDs) for an 8-day period. The willingness to pay threshold (WTP) was based on per capita GDP for 2022. . If the calculated Incremental Cost-Effectiveness Ratio (ICER) value is lower than the WTP threshold, it signifies that the intervention is cost-effective. Results The study included 95 women in each group of cervical cancer screening with VIA & HPV self-sampling. For eight days, the QALD was found to be 7.977 for the VIA group and 8.0 for the HPV group. The unit cost per woman screened by VIA and HPV self-testing was ?1,597 (US$ 19.2) and ?1,271(US$ 15.3), respectively. The ICER was ?-14,459 (US$ -173.6), which was much below the WTP threshold for eight QALDs, i.e. ? 4,193 (US$ 50.4). Conclusion The findings support HPV self-sampling as a cost-effective alternative to VIA. This informs policymakers and healthcare providers for better resource allocation in cervical cancer screening in Sikkim.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信